Researchers only
discovered this process in the late 1990s, but they've already begun dozens of clinical trials to gauge whether infusing
patients with these small RNAs works against a range of diseases, from
lung infections to liver
cancer to age - related macular degeneration, a sight - stealing condition that mainly affects people over the age of 50.
Alice Shaw recalls a signal moment in 2004 — just as she was finishing her oncology fellowship at MIT — when scientists
discovered that mutations in a gene for epidermal growth factor receptor (EGFR) were the culprits in about 10 to 15 percent of
lung cancer patients.
We're
discovering new genetic alterations driving
lung cancer, new drugs to target these alterations, and are refining our use of tests to find these alterations in individual patients,» says Dara Aisner, MD, PhD, investigator at the University of Colorado Cancer Center, molecular pathologist at CU School of Medicine Department of Pathology, and one of the panel ex
cancer, new drugs to target these alterations, and are refining our use of tests to find these alterations in individual
patients,» says Dara Aisner, MD, PhD, investigator at the University of Colorado
Cancer Center, molecular pathologist at CU School of Medicine Department of Pathology, and one of the panel ex
Cancer Center, molecular pathologist at CU School of Medicine Department of Pathology, and one of the panel experts.